Catalyst Wire Dossier Catalyst Wire Dossier

FH-FOLR1 CAR T-cell therapy

FH-FOLR1 chimeric antigen receptor T cell therapy · Fred Hutchinson Cancer Center
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for FH-FOLR1 CAR T-cell therapy, covering 2026-01-12 to 2026-01-12. Get the full timeline:

Most recent: Clinical Trial Update: FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

See pricing